Guidelines for Complications of Cancer Treatment Vol VIII Part B

9. Spriggs DR, Stopa E, Mayer RJ, et al. Fludarabinephosphate (NSC312878) infusions for the treatment ofacute leukemia: phase I and neuropathological study.Cancer Res 1986; 46:5953-5958.10. CG Moertel, TR Fleming, JS Macdonald, DG Hallerand JA Laurie, Hepatic toxicity associated withfluorouracil plus levamisole adjuvant therapy, J ClinOncol 11 (1993), pp. 2386–2390.11. Product information: xeloda(R), capecitabine. Nutley:Roche Pharmaceuticals, 2001, 2001d.12. Robinson K, Lambiase L, Jianjun L, et al. Fatalcholestatic liver failure associated with gemcitabinetherapy. Dig Dis Sci 2003; 148:1804-1808.13. Berkowitz RS, Goldstein DP, Bernstein MR. Ten year’sexperience with methotrexate and folinic acid as primarytherapy for gestational trophoblastic disease. GynecolOncol 1986; 23:111-118.14. RS Berkowitz, DP Goldstein and MR Bernstein, Tenyear’s experience with methotrexate and folinic acid asprimary therapy for gestational trophoblastic disease,Gynecol Oncol 23 (1986), pp. 111–118.15. Blum RH, Carter SK, Agre K. A clinical review ofbleomycin. A new antineoplastic agent. Cancer 1973;31:903-914.16. Venook A, Egorin M, Brown TD, et al. Paclitaxel (Taxol)in patients with liver dysfunction [Abstract]. Proc AmerSoc Clin Oncol 1994; 350:139.17. Issell BF, Crooke ST. Etoposide (VP-213). Cancer TreatRev 1979; 6:107-124.18. Johnson DH, Greco FA, Wolff SN. Etoposide-inducedhepatic injury: a potential complication of high-dosetherapy. Cancer Treat Rep 1983; 67:1023-1024.470